Middle East & Africa Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel

Description

List of Tables

The Middle East & Africa glaucoma therapeutics market was valued at US$ 518.94 million in 2023 and is expected to reach US$ 638.34 million by 2031; it is estimated to register a CAGR of 2.6% from 2023 to 2031.

Development of Novel Drug Delivery Methods Fuels Middle East & Africa Glaucoma Therapeutics Market

One of the most common treatment approaches for glaucoma management is to reduce intraocular pressure by using eye drops. Nonetheless, the rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market in the future. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the better bioavailability and efficacy of drugs. Sustained release (SR) implants and other innovative drug delivery systems aid in improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers associated with the treatment of primary open-angle glaucoma (POAG). As per an article published in PubMed Central in 2022, the only approved SR therapy for POAG by the FDA is Bimatoprost SR (DurystaTM) from Allergan plc. Bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are among other SR therapies that are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods is likely to remain a key trend in the glaucoma therapeutics market.

Middle East & Africa Glaucoma Therapeutics Market Overview

The Middle East & Africa glaucoma therapeutics market is categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The increasing prevalence of glaucoma in the geriatric population of the region and the rising government initiatives to spread awareness about the disease are fueling the growth of the glaucoma therapeutics market in the Middle East & Africa. According to an article published by IAPB in March 2020, congenital glaucoma, caused by an abnormality in the drainage outflow of the eye, is a leading cause of childhood blindness in Saudi Arabia. Approximately 8,000 children are estimated to have a functional low vision in the country. Children often suffer from severe conditions, necessitating multiple procedures and lifelong medical care, placing a significant social and economic burden on affected individuals and their families. Various research institutes in the region are engaged in developing and implementing treatments for glaucoma management. For instance, in an article published in JBI Evidence Implementation in June 2021, a pilot project implementation was inspected to evaluate adherence to evidence-based criteria and to introduce a modified clinical practice guideline (CPG) for treating patients with primary open-angle glaucoma (POAG) at a specialized eye care center in Riyadh, Saudi Arabia. The assessment showed that audit and feedback are effective tools for changing glaucoma practices in hospital in Saudi Arabia. This signifies that the project implementation can be generalized to promote evidence-based ophthalmology practices and may improve quality and consistency and optimize patients' care. Thus, the increase in research and development activities to treat glaucoma in the country is likely to support market growth during the forecast period.

Middle East & Africa Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Middle East & Africa Glaucoma Therapeutics Market Segmentation

The Middle East & Africa glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Middle East & Africa glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Middle East & Africa glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Middle East & Africa glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Middle East & Africa glaucoma therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Middle East & Africa glaucoma therapeutics market.

Product Code: BMIRE00031613

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Middle East & Africa Glaucoma Therapeutics Market - Key Market Dynamics

4.1 Glaucoma Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Mounting Incidence of Glaucoma Disease
- 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
4.3 Market Restraints
- 4.3.1 Medication Regimen Compliance Issues
4.4 Market Opportunities
- 4.4.1 Development of Wearable Technologies
4.5 Future Trends
- 4.5.1 Development of Novel Drug Delivery Methods
4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - Middle East & Africa Analysis

5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
5.2 Glaucoma Therapeutics Market Forecast Analysis

6. Middle East & Africa Glaucoma Therapeutics Market Analysis - by Drug Class

6.1 Beta Blockers
- 6.1.1 Overview
- 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.2 Alpha Adrenergic Agonists
- 6.2.1 Overview
- 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Prostaglandins Analogues
- 6.3.1 Overview
- 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Carbonic Anhydrase Inhibitors
- 6.4.1 Overview
- 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.5 Combination Drugs
- 6.5.1 Overview
- 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. Middle East & Africa Glaucoma Therapeutics Market Analysis - by Indication

7.1 Open Angle Glaucoma
- 7.1.1 Overview
- 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Angle Closure Glaucoma
- 7.2.1 Overview
- 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Middle East & Africa Glaucoma Therapeutics Market Analysis - by Distribution Channel

8.1 Hospital Pharmacy
- 8.1.1 Overview
- 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Retail Pharmacy
- 8.2.1 Overview
- 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Online Pharmacy
- 8.3.1 Overview
- 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Middle East & Africa Glaucoma Therapeutics Market - Country Analysis

9.1 Middle East & Africa
- 9.1.1 Middle East & Africa: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
  - 9.1.1.1 Middle East & Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.2.1 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.2.2 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.2.3 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.3 South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.3.1 South Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.3.2 South Africa: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.3.3 South Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.4 United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.4.1 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.4.2 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.4.3 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
  - 9.1.1.5 Rest of Middle East & Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.5.1 Rest of Middle East & Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
    - 9.1.1.5.2 Rest of Middle East & Africa: Glaucoma Therapeutics Market Breakdown, by Indication
    - 9.1.1.5.3 Rest of Middle East & Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

10.1 Growth Strategies in Glaucoma Therapeutics Market
10.2 Organic Growth Strategies
- 10.2.1 Overview
10.3 Inorganic Growth Strategies
- 10.3.1 Overview

11. Company Profiles

11.1 Alcon AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 AbbVie Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Bausch & Lomb Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Sun Pharmaceutical Industries Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Teva Pharmaceutical Industries Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Thea Pharma Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Santen Pharmaceutical Co., Ltd.
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms